Why Lucid Stock Is Sinking Today
Lucid stock posted big gains last week after the announcement of a robotaxi partnership with Uber, but it's pulling back today.
Comments from "Mad Money" host Jim Cramer could also be adding to bearish pressures today.
Lucid stock is still a speculative play, but the Uber partnership has the potential to be a major performance catalyst for the company.
10 stocks we like better than Lucid Group ›
Lucid Group (NASDAQ: LCID) stock is losing ground in Monday's trading. The electric vehicle (EV) specialist's share price was down 7.2% as of 2:45 p.m. ET amid the backdrop of a 0.5% gain for the S&P 500 index and a 0.7% gain for the Nasdaq Composite index.
The broader market is rallying again today, but the bullish momentum hasn't been enough to prevent sell-offs for Lucid stock. The company saw explosive valuation gains last week after it announced a partnership with Uber Technologies, but its stock is seeing a pullback as investors reassess the significance of the deal.
Lucid stock pulls back following big Uber deal pop
Last Thursday, Lucid and Uber announced a significant new robotaxi partnership. Uber will be purchasing 20,000 or more Lucid vehicles over the next six years and outfitting them with self-driving software from Nuro. Uber has also invested $300 million into Lucid. The news prompted a huge rally for Lucid stock, but the rally is losing steam today.
In addition to general profit taking on the stock, the extent of today's sell-off may also have roots in recent comments made by Mad Money host Jim Cramer. Speaking on his CNBC show, Cramer downplayed the significance of the deal and indicated that he didn't think that Lucid was a worthwhile investment.
What's next for Lucid?
As a speculative play in the EV market, Lucid stock will likely continue to see high levels of volatility. On the other hand, the company's partnership with Uber could wind up being a much bigger deal than Cramer is suggesting. For reference, the company delivered a total of 10,241 vehicles last year. While the Uber deal for 20,000 vehicle deliveries is spread out over six years, the figure is roughly double last year's sales total. Having its vehicles as a key part of Uber's robotaxi fleet also has the potential to create beneficial marketing impacts for Lucid.
Should you invest $1,000 in Lucid Group right now?
Before you buy stock in Lucid Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
6 minutes ago
- National Post
Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 2025
Article content Laserfiche is a Leader for the 10 th consecutive year, ranks highest in usability. Article content LONG BEACH, Calif. — Laserfiche — the leading SaaS provider of intelligent content management and business process automation — is a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for the 10 th year in a row. Among the vendors evaluated, Laserfiche ranks highest overall in usability. Download a copy of the report here. Article content 'As a leader in this year's Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities.' — Evelyn McMullen, Research Manager, Nucleus Research Article content 'As a leader in this year's Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities,' said Evelyn McMullen, research manager at Nucleus Research and author of the report. Article content Recently released Laserfiche AI-powered features are aimed at boosting productivity even further and enabling automation at scale. Smart Fields, an out-of-the-box intelligent capture tool, allows customers to extract data automatically using natural language instructions, no matter the source or format. Smart Chat provides an intuitive chat interface that enables users to quickly gain insights from their repository content. Article content 'As AI matures at an accelerated pace, vendors in the CSC market have the unique advantage of managing both structured and unstructured data from across the entirety of an organization,' the report's Market Overview states. Article content Laserfiche AI alongside powerful workflow automation, information governance and records management tools create new opportunities for organizational efficiency. Customers across industries use Laserfiche to increase productivity, create competitive advantage and drive growth. Article content 'Laserfiche gives us the forms and workflow processes as well as data integration that enable efficiency at scale,' said Airline Hydraulics Chief Technology Officer Todd Schnirel. 'Our Laserfiche-powered process improvements have supported us in achieving a significant increase in net revenue while adding very little operating expense.' Article content 'Being ranked a leader for 10 consecutive years is a testament to our product innovation,' said Thomas Phelps, senior vice president of corporate strategy and CIO at Laserfiche. 'Our top ranking in usability reflects our core value of putting people first and our commitment to delivering intuitive solutions that empower users.' Article content Laserfiche Article content is a leading enterprise platform that helps organizations digitally transform operations and manage their content with AI-powered solutions. Through scalable workflows, customizable forms, no-code templates and AI-enabled capabilities, the Laserfiche® document management platform accelerates how business gets done. Trusted by organizations of all sizes — from startups to Fortune 500 enterprises — Laserfiche empowers teams to boost productivity, foster collaboration, and deliver a superior customer experience at scale. Headquartered in Long Beach, California, Laserfiche operates globally, with offices across North America, Europe, and Asia. Article content | Article content X Article content | Article content LinkedIn Article content | Article content Facebook Article content | Article content Article content Article content Article content Article content Contacts Article content Media contact: Article content Article content Linda Domingo Article content Article content Article content Article content
CTV News
6 minutes ago
- CTV News
Five years after COVID, pharma shares languish in U.S. policy limbo
A vial of the Phase 3 Novavax coronavirus vaccine is prepared for a trial at St. George's University hospital in London on Oct. 7, 2020. (Alastair Grant / AP Photo) MILAN — Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived 'most-favored-nation' drug pricing rules in the lucrative U.S. market and potential 200 per cent tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11 per cent below its long-term average and 20 per cent below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. 'We've moved from cautious optimism to cautious pessimism,' said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. 'Valuations have gotten even cheaper, but for a reason,' she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. 'Armageddon scenario' Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. 'These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely,' he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total US$7.2 billion, down 41 per cent from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Catalyst needed Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unraveled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27 per cent discount, from parity to the S&P in 2023. 'Markets don't like uncertainty, and that shows up in valuations,' said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. 'Being cheap isn't necessarily a reason to buy. You need a catalyst.' For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. 'We're seeing companies go from unprofitable to very profitable,' he said, citing Alnylam and Penumbra as examples he owns. 'Historically, that's been a very good time to own healthcare stocks.' LFG+ZEST's Conca, who favors U.S. names like Abbott, Edwards Lifesciences, and AbbVie, along with Sanofi and Recordati in Europe, said interest rate cuts could be a major catalyst. Out of the woods? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55 per cent drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. 'The sector will adapt,' wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come 'at the cost of rebalancing its revenues and probably transforming its organizations.' AstraZeneca, for example, has unveiled a US$50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. 'Healthcare has endured a lot of pain,' said J.P. Morgan's Aliaga. 'We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been.' --- Reporting by Danilo Masoni; Editing by Amanda Cooper and Jane Merriman
Globe and Mail
36 minutes ago
- Globe and Mail
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
A significant shift is underway in the enterprise software landscape, particularly within the life sciences customer relationship management (CRM) market. Veeva Systems VEEV, a long-time partner of Salesforce CRM, has announced it will end its reliance on Salesforce's cloud infrastructure by September 2025. This strategic decision marks the beginning of Veeva's transition to its proprietary Vault platform, signaling a decisive move toward platform independence and deeper industry specialization. The split sets up a compelling faceoff between two companies now heading down very different paths. Veeva is sharpening its focus on life sciences by building vertically integrated solutions tailored to the sector's needs. At the same time, Salesforce is making a deliberate push into life sciences with its own purpose-built CRM offering. Both companies are accelerating investments in AI and product innovation, but their visions for capturing long-term growth are rapidly diverging. For investors, the key question is which company offers the stronger roadmap in this evolving market. Price Performance & Valuation of VEEV & CRM Shares of Veeva have gained 35.7%, while CRM stock has plunged 21.1% in the year-to-date period. From a valuation standpoint, CRM looks slightly more attractive than VEEV. According to the price-to-book ratio, Salesforce's shares currently trade at 4.15X, which is lower than Veeva's 7.50X. Platform Control & Industry Focus: Who Owns the Vertical? Veeva has long differentiated itself by serving a single industry—life sciences—with laser focus. That specialization is now reaching a new level as the company prepares to fully shift its CRM operations from Salesforce's infrastructure to its own Vault platform by September 2025. This move is more than just a tech transition. It gives Veeva full control over its software stack, allowing it to tailor features, optimize performance, and potentially expand margins without depending on a third-party host. More importantly, it strengthens Veeva's position as a vertically integrated player with deep regulatory and workflow understanding, something horizontal platforms often struggle to replicate in niche markets. Salesforce, meanwhile, brings the power of a highly adaptable and proven CRM infrastructure that serves thousands of enterprise customers across industries. Its recent push into life sciences through the introduction of a dedicated Life Sciences Cloud reflects a strategic intent to expand within this high-value vertical. While its approach is broader by design, Salesforce benefits from scale, flexibility, and a robust ecosystem that supports rapid customization through its platform tools. With the partnership ending, Salesforce now has the freedom to compete directly in life sciences CRM, and its entry could accelerate innovation and choice in the market without being constrained by a single client relationship. AI & Product Innovation: Whose Tech Vision Leads? Veeva is taking a focused approach to AI by building capabilities directly into its Vault platform. In April 2025, it launched Veeva AI, which integrates LLM agents and shortcuts across clinical, regulatory, and commercial apps. Features like Vault CRM Bot, Voice Control, and MLR Bot are set to roll out by late 2025, automating tasks such as pre-call planning and content compliance. Veeva also released the Direct Data API to enable faster, secure access to Vault data, supporting integrations with platforms like Snowflake and Databricks. These innovations are already gaining traction, with over 80 Vault CRM deployments and a goal of exceeding 200 by fiscal 2026. Salesforce is advancing AI at scale through Agentforce, a platform of prebuilt AI assistants embedded across its suite. Within 90 days of launch, Agentforce reached 3,000 paying customers and crossed $100 million in ARR. It connects with Tableau, MuleSoft, and Data Cloud to unify workflows and supports the Life Sciences Cloud Partner Network, which includes integrations with H1, ComplianceQuest, Box, and others. The company has also brought on AI-focused board members and continues to emphasize responsible adoption, aiming to augment human roles rather than replace them. The Road Ahead: Who's Better Positioned for CRM Leadership in Life Sciences? Veeva is focused on finalizing its shift to the Vault platform, aiming to boost margins and accelerate innovation with full control over its tech stack. Its AI roadmap, including tools like Vault CRM Bot and Voice Control, is designed to enhance productivity and compliance for life sciences users. With strong early adoption of Vault CRM and expanding enterprise relationships, Veeva is positioning itself as the go-to vertical platform for the sector. Salesforce is pursuing growth through its broad platform and expanding presence in life sciences via its dedicated cloud and AI-led offerings. Backed by a strong ecosystem and new integrations with healthcare partners, Salesforce is embedding Agentforce AI across its products. Its scale, flexibility, and ability to serve complex enterprise needs provide a strong foundation as it targets more specialized verticals like life sciences. How Do Zacks Estimates Compare for VEEV & CRM? The Zacks Consensus Estimate for VEEV's fiscal 2026 sales implies a year-over-year growth of 12.78%. For fiscal 2026, the earnings per share are projected to be $7.64, up 15.76% year over year. The earnings estimates have been trending upward over the past 60 days. The Zacks Consensus Estimate for CRM's fiscal 2026 sales and earnings implies year-over-year growth of 8.64% and 10.78%, respectively. The earnings estimates have been trending upward over the past 60 days. VEEV or CRM: Which Is the Smarter Buy? Veeva and Salesforce represent two powerful but contrasting approaches to the life sciences CRM market—one focused on deep vertical integration, the other leveraging broad enterprise reach. Veeva currently holds a Zacks Rank #2 (Buy), reflecting positive sentiment and growing confidence in its post-Salesforce roadmap. Its Growth Score of 'A' highlights strong potential in revenue acceleration, margin expansion, and product adoption. Salesforce, meanwhile, carries a Zacks Rank #3 (Hold) but also maintains a Growth Score of 'A', supported by its scale, product breadth, and AI-led innovation strategy. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Both companies are positioned for long-term relevance, but Veeva's focused strategy, platform control, and growing traction in life sciences give it the edge for investors seeking targeted exposure in this vertical. Salesforce remains a strong contender with scale and innovation, yet Veeva's clarity and execution make it the more compelling pick in this CRM faceoff. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report
